A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant

Trial Profile

A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Cytarabine; Etoposide; Folinic acid; Granulocyte colony-stimulating factors; Ifosfamide; Mesna; Methotrexate
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2017 Status changed from recruiting to completed.
    • 21 Feb 2017 Planned End Date changed from 1 Aug 2016 to 1 Dec 2017.
    • 22 Jun 2012 Actual initiation date (1 Nov 2011) and additional lead trial investigators (Pluta A, Hellmann A) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top